Skip to content
Trial Eligibility
Menu

PET Imaging of Noradrenergic Transmission in the Brain

NCT07686393

This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .

Summary

Background: Researchers have developed a new radioactive tracer (11C-ARMI). A tracer is a drug that attaches itself to other chemicals in the body and lights up so that the chemicals can be seen in imaging scans. The new tracer may be able to help them with many diseases, such as Alzheimer s disease and Parkinson s disease. Researchers want to test the new tracer in healthy people. Objective: To test a new tracer (11C-ARMI) during imaging scans of the brain and body in healthy people. Eligibility: Healthy people aged 18 years and older.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Healthy

Eligibility basics and study details

Study type
Interventional
Phase
Phase 1
Ages
18 to 105 years
Sex
All
Healthy volunteers
Accepted
Sponsor
National Institute of Mental Health (NIMH)
Last updated on ClinicalTrials.gov
September 29, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

Maryland · 1

  • National Institutes of Health Clinical Center · Bethesda, MD

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.